NASDAQ:MNPR
Monopar Therapeutics
Monopar Therapeutics's revenue was $0 in fiscal 2025.Summary generated from Monopar Therapeutics's SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−14.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | 0 | 0 |
| Operating income | −9 | −11 | −9 | −16 | −17 |
| Net income | −9 | −11 | −8 | −16 | −14 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Oct 2, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KRegulation FD disclosure
Jul 22, 2026 - 8-KRegulation FD disclosure
Jun 30, 2026 - 8-KRegulation FD disclosure
Jun 26, 2026 - 8-KResults of a shareholder vote
Jun 23, 2026